Bayer HealthCare has submitted VEGF Trap-Eye (aflibercept solution for injection) for regulatory approval in Japan to treat patients with myopic choroidal neovascularization (myopic CNV), one of the most common causes of eye disease. In ...
Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Bayer HealthCare's Eylea (aflibercept, solution for intravitreal injection) for the treatment of macular edema secondary to central retinal vein occlusion (CRVO). In ...
The European Commission has approved Regeneron Pharmaceuticals's Eylea (aflibercept) injection for the treatment of visual impairment caused by macular edema secondary to central retinal vein occlusion (CRVO). Eylea is a recombinant ...
Tags: fusion protein, Eylea
Sanofi and Regeneron Pharmaceuticals have announced the commencement of patient enrollment in two Phase 3 rheumatoid arthritis (RA) trials, the COMPARE and ASCERTAIN trials, with Sarilumab. The first fully human monoclonal antibody ...
Regeneron Pharmaceuticals and Bayer HealthCare have started a new Phase 3 VEGF Trap-Eye In Vision Impairment Due to DME (VIVID EAST-DME) trial of its Eylea (aflibercept) injection. Eylea, which is formulated as an iso-osmotic solution for ...
IBM will launch before midyear several new and improved collaboration and communication products, including a new suite for human resources tasks and a major upgrade of its Connections enterprise social networking product. The company, ...
Regeneron Pharmaceuticals has received Japanese Ministry of Health,Labour and Welfare(MHLW)approval for its Eylea(aflibercept)injection to treat patients with neovascular age-related macular degeneration(wet AMD)symptoms. Regeneron chief ...
Tags: Regeneron Pharmaceuticals, Eylea Injection, wet AMD, George Yancopoulos
The US Food and Drug Administration (FDA) has approved ZALTRAP (ziv-aflibercept) injection to be used in combination with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI) to treat patients with metastatic colorectal cancer (mCRC) that is ...
Tags: Zaltrap Injection, Medicine
Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin has signed a co-promotion agreement with Santen Pharmaceutical for Eylea (aflibercept) injection in Japan. Eylea is approved for sale in the US and Australia for the treatment of ...
Sanofi and Regeneron Pharmaceuticals have received FDA priority review for the biologics license application (BLA) of ZALTRAP (aflibercept) as a treatment for metastatic colorectal cancer (mCRC). The filing was based on the Phase III ...